Sparsentan

3 trials 1 recruiting Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

1 Sponsors

14 Countries

Phase III

Phase II

Phase III: 2 Phase II: 1

Indications tested

IgA nephropathy 2 Focal segmental glomerulosclerosis 2 Alport's syndrome 1

Sponsors using this IMP

Travere Therapeutics Inc. 3

All trials

3 total

Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney diseases. Recruiting

2023-505497-14-00 Phase II 6 countries Travere Therapeutics Inc.
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Phase III 11 countries Travere Therapeutics Inc.
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Phase III 12 countries Travere Therapeutics Inc.

Showing 1–3 of 3 trials

← All drugs A–Z